Bazedoxifene is a selective estrogen receptor modulator (SERM) combined with conjugated estrogens and is used as an alternative to traditional estrogen-progestin therapy for menopausal symptoms in women with a uterus. It provides relief from vasomotor symptoms and protects the endometrium without the need for added progestin, making it suitable for women who cannot tolerate progestogens. This combination is typically considered a second-line option for women seeking non-progestin hormonal therapy. Common side effects include muscle spasms, nausea, and abdominal pain; there is also a potential increased risk of venous thromboembolism. It is not recommended for women with a history of thromboembolic disease or estrogen-sensitive cancers.